A phase III, randomized, double-blind, placebo-controlled study of the safety and efficacy of adefovir dipivoxil (Bis-POM PMEA) in prolonging survival of HIV-infected individuals with a CD4+ cell count of <=100/mm3 or with a CD4+ cell count both >100 and <= 200/mm3 and a nadir CD4+ cell count of <= 50/mm3

Trial Profile

A phase III, randomized, double-blind, placebo-controlled study of the safety and efficacy of adefovir dipivoxil (Bis-POM PMEA) in prolonging survival of HIV-infected individuals with a CD4+ cell count of <=100/mm3 or with a CD4+ cell count both >100 and <= 200/mm3 and a nadir CD4+ cell count of <= 50/mm3

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2009

At a glance

  • Drugs Adefovir dipivoxil (Primary)
  • Indications Cytomegalovirus infections; HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Sep 2008 Actual start date (Dec 1996) added as reported by CT.gov
    • 25 Sep 2008 Actual patient number (505) added as reported by CT.gov
    • 25 Sep 2008 Planned end date (Jan 1999) added as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top